The current strength of the medical device sector comes from the growing acceptance that change is coming and, if it’s handled properly, it can be good for medtech. To be sure, device companies in 201
Medtronic PLC ’s reporting of disappointing results from its SYMPLICITY renal denervation trials cast a bit of a pall over discussions at the JP Morgan Health Care Conference in San Francisco ear